Insulet (Nasdaq:PODD) stock is up today — a day after releasing Q2 results that blew past the consensus revenue forecast. The Acton, Massachusetts–based automated insulin delivery technology developer yesterday evening posted losses of $35 million, or 50¢ per share, on sales of $299.4 million for the three months ended June 30, 2022, for a $10 […]
Technology
Tandem sinks on Q2 misses, slashed sales guidance
Tandem Diabetes Care (Nasdaq:TNDM) shares took a bit hit after hours on second-quarter results that missed the consensus forecast. Shares of TNDM were down 7.2% at $64 per share after the market closed, which was when it released its quarterly results. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device […]
Anthem to provide coverage for Senseonics’ next-gen CGM
Senseonics (NYSE:SENS) announced today that Anthem is providing coverage for implantable continuous glucose monitoring (CGM). The coverage extends to the Eversense CGM system — including the recently launched next-generation Eversense E3 180-day CGM — meaning that Senseonics’ global commercial partner, Ascensia Diabetes Care, can introduce the CGM to more people living with diabetes. Germantown, Maryland-based […]
Insulet begins full market launch for Omnipod 5
Insulet (Nasdaq:PODD) announced today that it commenced the full market launch for its next-generation Omnipod 5 system. The Omnipod 5 automated insulin delivery (AID) system has now been made fully available through U.S. retail pharmacy channels for individuals aged six years and older with type 1 diabetes. Acton, Massachusetts-based Insulet received FDA clearance for Omnipod […]
How Medtronic aims to address health inequities in diabetes
Fueled by personal experience, Maribel Baker leads Medtronic’s diabetes business toward improving health equity. At 15 years old, Maribel Baker’s life was in the balance. While growing up in Panama, Baker had to undergo leg surgery because she was born with one leg shorter than the other. Following the surgery, she learned that she had […]
BD buys MedKeeper and its connected pharmacy software for IV workflow
BD (NYSE:BD) announced today that it acquired cloud-based pharmacy management application developer MedKeeper. Franklin Lakes, N.J.-based BD said in a news release that MedKeeper strategically complements its existing presence in the pharmacy, with solutions for compounding, logistics workflow, controlled substance management and inventory optimization. MedKeeper’s platform will be made part of BD’s existing portfolio of […]
Better Therapeutics completes trial for type 2 diabetes treatment, will submit to FDA
Better Therapeutics (Nasdaq:BTTX) announced today that it completed the pivotal trial for its BT-001 digital therapeutic for diabetes. San Francisco-based Better Therapeutics designed its nutritional cognitive behavioral therapy (nCBT) platform to address the root causes of cardiometabolic diseases. It designed its investigational, first-in-class BT-001 prescription digital therapeutic (PDT) to use nCBT to treat type 2 […]
Dexcom launches G6 mobile app in Spanish
Dexcom (Nasdaq:DXCM) announced today that it launched its G6 continuous glucose monitor (CGM) mobile app in Spanish. San Diego-based Dexcom’s G6 mobile app in Spanish has been made available immediately for users with a compatible iOS (v1.10.1) or Android (v1.10.0) smart device. The company said in a news release that diabetes disproportionately impacts Latinos. As […]
Study backs One Drop’s AI-powered blood glucose forecasts in diabetes outcomes
One Drop announced today that a study of its AI-powered blood glucose forecasting technology leads to improved diabetes outcomes. New York-based One Drop published outcomes from a retrospective cohort study in the Journal of Medical Internet Research (JMIR). The study focused on indicators of glycemic control and health data logging in adults with type 2 diabetes using […]
Zillion partners with Dexcom on CGM integration
Zillion announced today that it partnered with Dexcom (Nasdaq:DXCM) to integrate its CGM technology with Zillion’s digital health platform. Needham, Massachusetts-based Zillion will connect Dexcom’s continuous glucose monitoring (CGM) platform with its digital health offering for the RestoreHealth program, enhancing RestoreHealth for employer and health system patients. “Type 2 diabetes continues to be a growing […]